awmsg logo



botulinum toxin type A (Botox®)


Reference No. 1429

Publication date:
13/12/2013


Appraisal information

botulinum toxin type A (Botox®) 200 units powder for solution for injection
botulinum toxin type A (Botox®) 100 units powder for solution for injection
botulinum toxin type A (Botox®) 50 units powder for solution for injection


Company: Allergan Ltd
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: 23/10/2013
AWMSG meeting date: 20/11/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 3013
Ministerial ratification: 06/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Botulinum toxin type A (Botox®) is recommended as an option for use within NHS Wales for the management of urinary incontinence in adult patients with neurogenic detrusor overactivity due to subcervical spinal cord injury (traumatic or non-traumatic) or multiple sclerosis, who are not adequately managed with anticholinergics; patients should be already catheterising or willing and able to catheterise if required.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download